lomustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 96 Diseases   29 Trials   29 Trials   1185 News 
46 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lomustine / Generic mfg.
2007-005802-38: Evaluation of efficacy and safety of the new drug AP 12009 in adult patients suffering from Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) compared to standard treatment with Temozolomide or Lomustine: A clinical study where patients will be openly and randomly assigned to one of the treatment groups to gain marketing approval for the new drug AP 12009.

 
3
27
Europe
AP 12009, AP 12009, Temodal, Carmubris, Cecenu, Temodal, Carmubris, Cecenu
Antisense Pharma GmbH, Antisense Pharma GmbH,
Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or secondary Glioblastoma (WHO grade IV)
 
01/12
NCT00085735 / 2009-010004-28: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Completed
3
549
Europe, Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Craniospinal Irradiation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Involved-Field Radiation Therapy, IFRT, Involved field radiotherapy, Laboratory Biomarker Analysis, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Medulloblastoma
03/16
12/24
2018-004250-17: International Trial for Patients with High Risk Medulloblastoma

Ongoing
3
850
Europe
Thiotepa, Vincristine, Lomustine, Cyclophosphamide, Temozolomide, Carboplatin, Cisplatin, [Thiotepa], [VIncristina solfato], [Lomustine], [Ciclofosfamide], [Temozolomide], [Carboplatino], [Cisplatino], Powder for concentrate for solution for infusion, Solution for injection/infusion, Capsule, hard, Powder for solution for injection/infusion, Concentrate for solution for infusion, TEPADINA, Vincristine Sulphate 1 mg/ml Injection, Lomustine "medac", Cyclophosphamide, Temodal®, Carboplatin, Cisplatin
University of Birmingham, UNIVERSITY OF BIRMINGHAM, Cancer Research UK, , Barncancerfonden
Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-wingless-type (WNT) (Groups 3 and 4) medulloblastoma, with at least one additional high risk feature, Brain tumour, Diseases [C] - Cancer [C04]
 
 
2018-005027-16: Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma Verbesserung des funktionellen Ergebnisses für PatientInnen mit neu diagnostizierten Grad II oder III-Gliom

Not yet recruiting
3
406
Europe
Lomustine, Capsule, Solution for injection, Temodal
Ruprecht-Karls University Heidelberg Medical Faculty, represented by Heidelberg University Hospital, Federal Ministry of Education and Research
WHO grade II or III glioma, brain tumor, Diseases [C] - Cancer [C04]
 
 
2020-003545-11: A randomized study to comparelomustine with lomustine and bevacizumab for patients with recurrent malignant brain tumors. Et lodtrækningsorsøg for at sammenlignelomustine med lomustine plus bevacizumab til patienter med tilbagefald af ondartet hjernetumor

Not yet recruiting
3
168
Europe
lomustine, Zirabev, Capsule, Solution for infusion, lomustine, Zirabev
Rigshospitalet, Danish Regions
recurrent glioblastoma glioblastom tilbagefald, recurrent malignant brain tumor Tilbagefald af ondaret hjernetumor, Diseases [C] - Cancer [C04]
 
 
STELLAR, NCT02796261 / 2016-000089-45: Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Active, not recruiting
3
343
Europe, Canada, US
Eflornithine, DFMO, Lomustine, CCNU, CeeNU, Gleostine
Orbus Therapeutics, Inc.
Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
06/23
06/23
NCT06419946: Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Not yet recruiting
3
200
NA
Temozolomide, TMZ, Lomustine, LOM
Vastra Gotaland Region, Skane University Hospital, Gävle Hospital, Karolinska Institutet, Sahlgrenska University Hospital, Sweden, Karlstad Central Hospital, Ryhov County Hospital, Kalmar County Hospital, Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, Sorlandet Hospital HF, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Umeå, Eskilstuna Lasarettet, Region Örebro County
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
12/28
12/31
NRG-BN011, NCT05095376: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting
3
306
Canada, US
Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Photon Beam Radiation Therapy, Photon EBRT, Photon External Beam Radiotherapy, Radiation, Photon Beam, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
NRG Oncology, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
08/26
08/31
LEGATO, NCT05904119: Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Recruiting
3
411
Europe, RoW
Lomustine, Reirradiation
European Organisation for Research and Treatment of Cancer - EORTC, Swiss Group for Clinical Cancer Research
First Progression of Glioblastoma
09/27
02/28
NCT05382338: A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Suspended
3
225
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Sodium Thiosulfate, Cyanide Antidote Package, Disodium Thiosulfate, S-Hydril, Sodium Hyposulfate, Sodium Thiosulfate Pentahydrate, Sodium Thiosulphate, Sodothiol, Thiosulfate, Sodium, Pentahydrate, Thiosulfuric Acid Disodium Salt, Survey Administration, Vincristine, LCR, Leurocristine, VCR, Vincrystine
Children's Oncology Group, National Cancer Institute (NCI)
Medulloblastoma
12/27
12/27
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Recruiting
3
560
Europe, US
SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal
CarThera
Glioblastoma, Recurrent Glioblastoma, GBM
01/28
06/28
ImproveCodel, NCT05331521: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).

Recruiting
3
406
Europe
CETEG, Lomustine (CCNU) and Temozolomide, PCV, Procarbazine, Lomustine and Vincristine, RT, Radiotherapy
University Hospital Heidelberg, Universitätsmedizin Mannheim, Ruhr University of Bochum
Oligodendroglioma
03/29
03/29
2016-001797-15: A trial testing an alternative high-dose, intermittend scheduling for sunitinib in patients with recurrent brain cancer Een onderzoek met hoge dosis sunitinib bij patiënten met terugkerende hersenkanker

Ongoing
2/3
100
Europe
Sunitinib, Lomustine, L01XE04, L01AD02, Capsule, Sutent, Belustine
VU University Medical Center, Department of Medical Oncology, VU University Medical Center, Deparment of Medical Oncology
- Glioblastoma multiforme (GBM) - Glioblastoma, - Brain cancer - Glioblastoma - Malignant Brain Tumor, Diseases [C] - Cancer [C04]
 
 
STELLAR, NCT03025893: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

Recruiting
2/3
100
Europe
Sunitinib, Sutent, Lomustine, CCNU
Amsterdam UMC, location VUmc
Glioblastoma Multiforme, Glioblastoma, Adult, Glioblastoma, Recurrent Brain Tumor, GBM
01/22
01/22
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT02066220 / 2011-004868-30: International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Active, not recruiting
2/3
360
Europe, RoW
Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Cisplatin, Lomustin (CCNU), Vincristine, Cyclophosphamide, Radiotherapy with Carboplatin, Carboplatin, Maintenance chemotherapy, Lomustine (CCNU), WNT-HR < 16 years, WNT-HR >= 16 years, Induction Chemotherapy, SHH-TP53 M0, SHH-TP53 M+ (germline), SHH-TP53 (somatic), Vinblastin Maintenance
Universitätsklinikum Hamburg-Eppendorf, Deutsche Kinderkrebsstiftung
Brain Tumors
12/26
12/26
R-2, NCT05898451: Effect of Refnot on Immunity in Cancer Patients

Completed
2
55
NA
Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T), Refnot, Tumor necrosis factor-thymosin alfa 1 recombinant, Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy, and Dacarbazine, Lomustine, Cisplatin
Refnot-Pharm Ltd
Solid Tumor
11/11
11/11
NCT01582269 / 2011-004418-40: A Study in Recurrent Glioblastoma (GB)

Completed
2
151
Europe, Canada, US, RoW
LY2157299 monohydrate, LY2157299, Lomustine, Placebo, LY2157299 monohydrate-matched placebo
Eli Lilly and Company
Glioblastoma
07/14
10/24
2006-007083-28: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.

Ongoing
2
60
Europe
prednisone, chlorambucil, etoposide, lomustine, 90Y-ibritumomab tiuxetan, A07EA03, Mabthera, Zevalin, Mabthera, Zevalin
HOVON foundation, KWF, Spectrum Pharmaceuticals
Aggressive B-cell NHL
 
 
2009-012186-63: Landelijke Werkgroep voor Neuro-Oncologie trial (LWNO 0901)Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in patients with recurrent Glioblastoma: the BELOB trial

Ongoing
2
86
Europe
Avastin, Belustine, Avastin, Belustine
Erasmus MC, more specifically for and on behalf of the department of Neurology/Neuro-Oncology
Patients with recurrent glioblastoma multiforme who failed combined chemo-irradiation with temozolomide.
 
 
2011-000900-16: A randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma

Ongoing
2
52
Europe
Axitinib, Lomustine, AG-013736, Cecenu (Lomustine), Cecenu (Lomustine)
UZ BRUSSEL, UZ Brussel
• Patients with recurrent central nervous system glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation therapy and alkylating chemotherapy. • No concomitant treatment with enzyme inducing anti-epileptic drugs (EIAED)
 
 
2019-004053-91: BRIOChe: A trial looking at re-irradiation and chemotherapy in patients with recurrent glioblastoma.

Not yet recruiting
2
70
Europe
Lomustine, Procarbazine, Vincristine, Capsule, Injection, Lomustine medac, Vincristine
University of Leeds, The Jon Moulton Charity Trust
Recurrent Glioblastoma, Brain tumour, Diseases [C] - Cancer [C04]
 
 
NCT03463265: Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Completed
2
62
US
nab-sirolimus, nab-sirolimus + temozolomide, temozolomide, nab-sirolimus + bevacizumab, bevacizumab, nab-sirolimus + lomustine, lomustine (CCNU), nab-sirolimus + marizomib (MRZ), marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy, radiation
Aadi Bioscience, Inc.
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
08/22
08/22
2020-005429-10: Romiplostim for thrombocytopenia induced by lomustine at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study Romiplostim para el tratamiento de los niveles bajos de plaquetas provocados la quimioterapia con lomustina en pacientes con la primera recurrencia (reaparición del crecimiento) de un tumor cerebral, glioblastoma con metilación de MGMT

Not yet recruiting
2
100
Europe
romiplostim, [NA], Powder for solution for injection, Nplate
European Organisation for Research and Treatment of Cancer EORTC, EORTC AISBL/IVZW, Amgen Europe B.V., European Organisation for Research and Treatment of Cancer (EORTC)
thrombocytopenia caused by chemotherapy drug lomustine trombocitopenia inducida por lomustina, Low platelets due to bone marrow suppression caused by chemotherapy drug lomustine niveles bajos de plaquetas provocados la quimioterapia con lomustina, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
RIGOLETTO, NCT04933942 / 2020-005429-10: Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma

Withdrawn
2
100
Europe
Lomustine, Romiplostim
European Organisation for Research and Treatment of Cancer - EORTC, Amgen
First Progression of MGMT Promoter-methylated Glioblastoma
12/22
12/22
ChiCTR2000035315: A Randomized, Open, Controlled, Multi-Centre, Phase II Clinical Study to Evaluate the Efficacy and Safety of ACT001 Monotherapy and the Combination of ACT001 with Temozolomide VS Temozolomide or Lomustine Alone in Patients with Recurrent Glioblastoma

Not yet recruiting
2
75
 
ACT001 alone ;ACT001 and TMZ combined group ;CCNU or TMZ control
General Hospital of Tianjin Medical University; General Hospital of Tianjin Medical University, funds raise by sponsor
Glioblastoma
 
 
GLIOSTELLA, NCT06336291: A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Not yet recruiting
2
90
US
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
06/26
06/26
NCT06177964: Lerapolturev (PVSRIPO) in GBM

Recruiting
2
92
US
Lerapolturev, Lomustine Pill
Darell Bigner, Istari Oncology, Inc.
Recurrent Supratentorial Glioblastoma
02/29
02/29
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT04863950: Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Recruiting
2
25
US
Lomustine, Gleostine, Imipramine Hydrochloride, Trofranil
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
09/26
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT06325683: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Suspended
2
184
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Relatlimab, BMS 986016, BMS-986016, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Recurrent Glioblastoma
07/28
07/28
LEAHRN, NCT02724579: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Active, not recruiting
2
45
Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Laboratory Biomarker Analysis, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Gleostine, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine, LCR, Leurocristine, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Medulloblastoma
06/27
06/27
NCT04049669: Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Recruiting
2
140
US
Indoximod, Partial Radiation, Full-dose Radiation, Temozolomide, Cyclophosphamide, Etoposide, Lomustine
Theodore S. Johnson, National Cancer Institute (NCI), Augusta University, Emory University
Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
10/25
10/27
PersoMed-I, NCT04402073 / 2020-003063-26: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Active, not recruiting
2
20
Europe, RoW
Sonidegib, Cisplatin, Lomustine, Vincristine, radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC, EORTC-BTG, Sunpharmaceuticals
Medulloblastoma
04/25
04/25
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25
NCT04910022 / 2020-003417-35: Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Recruiting
1/2
150
Europe, US
NMS-03305293, Temozolomide
Nerviano Medical Sciences, Nerviano Medical Sciences S.r.l, Nerviano Medical Sciences S.r.l.
Glioblastoma, Diffuse Glioma
06/25
11/25
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT01682187: A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Completed
1
66
Europe, US
LY2157299, Lomustine
Eli Lilly and Company
Glioma
05/12
09/24
NCT03425292: A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Completed
1
49
US
Temozolomide, temodar, conformal brain radiation therapy, Nivolumab, opdivo, Ipilimumab, yervoy, Bevacizumab, avastin, 5-day Temozolomide, Lomustine, CCNU, Nivolumab monotherapy
Saint John's Cancer Institute
Newly Diagnosed High Grade Glioma
09/22
10/23
GLIOASTRA, NCT05304663: Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Withdrawn
1
24
NA
Onfekafusp alfa, L19TNF, Lomustine
Philogen S.p.A.
Glioblastoma
12/24
12/24
MAGIC-G1, NCT05324501: A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

Active, not recruiting
1
36
US
MTX110, Programmable pump and catheter system
Biodexa Pharmaceuticals
Recurrent Glioblastoma
08/28
08/28
ChiCTR-OOC-15005759: A study to evaluate the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation

Recruiting
N/A
100
 
PCV Chemotherapy (Lomustine/vincristine/c kappa hydrazine)
Tiantan Hospital, Capital Medical University; Heibei Yanda Hospital; Hebei Yanda Hospital, Supported by Hebei Yanda Hospital
Recurrent High-grade Glioma
 
 
RECSUR, NCT06283927: The -study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

Recruiting
N/A
464
Europe, US
Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Immunotherapy, Oncolytic virotherapy, Best supportive care
Jasper Gerritsen, Haaglanden Medical Centre, Universitaire Ziekenhuizen KU Leuven, University Hospital Heidelberg, Technical University of Munich, Insel Gruppe AG, University Hospital Bern, Massachusetts General Hospital, University of California, San Francisco
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
01/27
01/28
NCT05410301: Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

Withdrawn
N/A
30
US
Static Magnetic and Electric (sBE) device, Lomustine, Bevacizumab
Varun Monga, MD, University of Iowa
Glioblastoma, Recurrent Glioblastoma
08/26
08/26

Download Options